

ASIA PACIFIC



QUANTITATIVE RESEARCH



CIMB Analyst(s)

**Eben VAN WYK, CFA**

T (61) 2 9694 6058
E eben.van.wyk@cimb.com

Rohit SHARMA

T (852) 25391313
E rohit.sharma@cimb.com

Sushil KEDIA, FRM

T (91) 22 6602 5209
E sushil.kedia@cimb.com

Wei LU

T +61 2 9694 6069
E wei.lu@cimb.com

Alpha evidence for target prices and analyst recommendations

Scholarly research shows the investment potential of revisions in analyst recommendations and target prices, with an emphasis on the value of combining different types of analyst forecast data in order to identify predictions of high conviction.

Figure 1: CIMB analyst coverage universe alpha screen

BB ticker	Company	From	To	Days	Rec score	From	To	Days	TP score	Total score
		rec	rec	since rev		TP	TP	% chg		
Stocks predicted to outperform according to these ideas										
2727 TT	Wowprime Corp	N	O/P	1	0.98	435.00	555.00	28%	1	0.98
AAX AU	Ausenco	N	O/P	7	0.84	1.61	2.89	80%	7	0.84
FNP AU	Freedom Foods	N	O/P	19	0.65	1.65	2.47	50%	19	0.65
NAB AU	National Australia Bank	N	O/P	21	0.62	31.72	35.02	10%	21	0.62
3231 TT	Wistron Corp	N	O/P	21	0.61	29.00	38.00	31%	21	0.61
RHBC MK	RHB Capital Bhd	N	O/P	83	0.15	9.90	11.30	14%	9	0.81
BKW AU	Brickworks	N	O/P	5	0.90	13.96	14.33	3%	5	0.00
1913 HK	Prada SpA	N	O/P	264	0.00	80.00	90.00	13%	7	0.85
SIE SP	SIA Engineering	N	O/P	7	0.85	5.00	5.20	4%	7	0.00
Stocks predicted to underperform according to these ideas										
SGRO IJ	Sampoerna Agro	N	U/P	21	-0.62	2000.00	960.00	-52%	21	-0.62
EYSAN SP	Eu Yan Sang Int'l	O/P	U/P	28	-0.52	0.89	0.75	-16%	28	-0.52
BLY AU	Boart Longyear	N	U/P	29	-0.51	0.69	0.36	-48%	29	-0.51
BANPU TB	Banpu	N	U/P	2	-0.97	280.00	277.00	-1%	2	0.00
PRA SP	Parkson Retail Asia	O/P	U/P	34	-0.46	1.88	1.38	-27%	34	-0.46
891 HK	Trinity	N	U/P	34	-0.46	3.30	2.40	-27%	34	-0.46
RBXY IN	Ranbaxy Laboratories	N	U/P	7	-0.85	320.00	290.00	-9%	7	0.00
1836 HK	Stella Int'l Holdings	O/P	U/P	37	-0.42	24.90	14.10	-43%	37	-0.42
028670 KS	STX Pan Ocean	N/R	U/P	40	0.00	1380.00	295.00	-79%	12	-0.75
SOURCE: CIMB										

We highlight valuable ideas from a recent book titled “The alpha interface: Forty trading strategies based on scientific findings about analyst forecasts”, authored by Dr Jeffrey Mishlove in the US. With permission from the author, we proceed with a series of notes on his books.

Recommendation changes add value ➤

Several academic studies show that revisions in analyst recommendations are able to predict share price performance. A study covering the G7 countries finds strong abnormal returns for stocks with recent upgrades and downgrades, especially in the US and Japan.

Upgrade to what? ➤

An upgrade to ‘buy’ is more effective than an upgrade to ‘hold’, ie, the recommendation level matters when looking at revisions.

Target price revisions ➤

Revisions in target prices only add value if they don’t conflict with the analyst’s recommendation, ie, you should buy into target price upgrades only for stocks with a current ‘buy’ recommendation.

Initiations outperform ➤

Initiations of coverage generally lead to a permanent increase in liquidity and subsequent share price appreciation.

BACKGROUND

I recently came across this insightful series of books by Dr Jeffrey Mishlove, who shares my thirst for new alpha and has frankly made our job a lot easier. With sincere gratitude to the author, we highlight a few papers referred to in the first book of the 'alpha interface' series. We believe that these sensible ideas offer new ways to profitably apply analyst recommendations and target prices in a more holistic way.

The aim of this review is to stimulate debate on the topic of analyst forecast information, which will be followed up by empirical testing and potentially new hypotheses about the predictive value of this data and how to best apply it in Australia and the rest of Asia.

Table 1 on the front page recommends stocks to buy and sell based on these ideas. This quantitative screen takes advantage of CIMB's broad coverage of almost 1,000 stocks across Asia. The exact workings of the quantitative metrics are explained towards the end of this document.

ANALYST RECOMMENDATIONS AND TARGET PRICES

Capturing price trends after recommendation changes ➤


Changes in analyst recommendations help predict future price trends

The market pays attention when analysts revise their recommendations from negative to positive and vice versa. Boni and Womack (2006) show that consensus buy/hold/sell recommendations have no predictive value on their own because a lot of this information tends to be quite stale. However, recommendation changes have strong predictive value, especially within industries.

Jegadeesh and Kim (2006) investigate this idea for all the G7 countries including the US, Japan, UK, France, Germany, Italy and Canada on a large sample of IBES data between 1993 and 2002. They find that US shares experience the strongest price trends after recommendation revisions, followed by Japan. In their study, upgrades are usually followed by positive price momentum, and vice versa for downgrades.

The next chart shows the average performance, by country, over a one month period after a typical upgrade or downgrade. Returns are relative to the local market index. In their study the US market provides the largest opportunity for predicting stock returns from recommendation changes.

Figure 2: Event study 1m after recommendation changes – abnormal returns



Analysts tend to follow share prices, but do have some skill in predicting the continuation of trends. The next two charts show that upgrades tend to happen after a run-up in the share price (and vice versa for downgrades) and the trend in the share price tends to continue thereafter, allowing investors to benefit from following recommendation revisions. These charts are event studies showing the average cumulative abnormal returns for the two weeks (10 working days) before and two weeks after upgrades and downgrades in each country. On the horizontal axes, '0' indicates the day of the upgrade or downgrade event.

Figure 3: Cumulative abnormal event returns around upgrades





Figure 4: Cumulative abnormal event returns around downgrades



SOURCE: JEGADEESH & KIM, JOURNAL OF FINANCIAL MARKETS, 2006

A realistic long-short back test demonstrates significant alpha within the majority of G7 countries

The authors simulate a long-short investment strategy that buys a portfolio of recent upgrades and sells a portfolio of recent downgrades. Their thorough analysis is split between small versus large companies and equal versus market cap weighting, as well as showing the impact of trading on delayed information.

For institutional investors the most realistic back test is shown below, for large companies (above the median size within the stock universe) using market cap weighted portfolios with a holding period of one month. In this back test, the US market delivers 23% pa when trading at the close on days with recommendation revisions. This deteriorates to 7% pa if trading is at the close of the next day. In reality the opportunity may lie somewhere in-between, because there is often a delay due to the late arrival of data and the time it takes to process and analyse information. Japan and Canada also produce statistically and economically significant profits in the back test.

Figure 5: Long-short portfolio back test for recommendation changes (annualised)

	No delay	1 day delay	5 day delay
US	23%	7%	2%
Japan	18%	9%	5%
Canada	11%	5%	-2%
Germany	8%	4%	5%
Britain	7%	5%	4%
Italy	4%	0%	2%
France	2%	-2%	0%

SOURCE: JEGADEESH & KIM, JOURNAL OF FINANCIAL MARKETS, 2006

An interesting observation from Boni and Womack (2006) is that recommendation changes are not very useful on an aggregated industry or sector level. Their back test improves considerably when their investment strategy is implemented on a sector-neutral basis. It suggests that analysts are not good at evaluating the relative potential of their sectors overall, but are very good at predicting the future relative performance of stocks within their sectors.

Barber et al show in a 2003 paper that the market turned sharply against US analyst recommendations in 2000-2001 after the peak in the tech bubble, which effectively reduced the significance and understates the effect of analyst recommendation changes in the pre-2000 period. It serves as a warning that strategies like these can potentially suffer big draw-downs during and after periods of great market volatility, as we experienced again after 2007.

Recommendation levels and double revisions ➔


Recommendation upgrades and downgrades are most effective when used in conjunction with the level of a recommendation, ie, upgrades to 'buy' are better than upgrades to 'hold'

A more recent US study by Barber and Lehavy (2010) finds that recommendation levels actually have predictive value when used in conjunction with recommendation changes. For example, a stock upgraded to 'buy' or 'strong buy' significantly outperforms a stock upgraded to 'sell' or 'hold'. Stocks double-upgraded or double-downgraded, eg, from 'hold' to 'strong buy', deliver similar results. Their data is more extensive than previous studies, covering the period from 1986 to 2006.

The next chart and table summarise the annualised long versus short performance of their different back-tested investment strategies (numbers may be subject to rounding errors). The first two columns are for strategies that combine recommendation changes and levels, the third for recommendation levels only, and the last two for recommendation changes only. Clearly, all the different types of information – recommendation levels as well as changes - add value, but they work best when combined.

The first column in the chart is for a strategy that goes long the stocks that are upgraded two levels to 'buy' or 'strong buy' and short stocks downgraded two levels to 'sell' or 'strong sell'. The long portfolio earns 5.8% pa and the short portfolio earns -7.3% pa (ie, 13% pa long-short), after adjusting for beta, size, value and momentum effects. The second column is similar to the first, but for revisions of one level only, which actually performs slightly better. The third column is for a strategy that goes long all 'buy' and 'strong buy' recommendations and short all 'sell' and 'strong sell' recommendations, irrespective of the direction of the revision. The level of recommendation therefore adds unique information when the data is not stale (ie, the recommendation was recently revised). The last two columns show the profit to strategies based on double and single revisions, irrespective of the new recommendation level.

Figure 6: Annualised abnormal returns from combined recommendation levels/changes strategy



SOURCE: BARBER ET AL, FINANCIAL MANAGEMENT, 2010

Target price upgrades and downgrades are quite effective when used in conjunction with the level of a recommendation


Target price revisions and recommendations ➤

Kanne et al (2012) came up with very interesting results on 12-month analyst target prices. In this study of US data, across 2001 to 2007, they find that revisions in target prices tend to predict future price moves very well, as long as there is no conflict with the analyst's own recommendation level. In other words, a target price upgrade is only useful if the analyst has a 'buy' or 'strong buy' on the stock, and vice versa for a target price downgrade.

The authors use target price revisions in conjunction with analyst recommendation levels to filter out those revisions that are expected to be more predictive than others, ie, separating signals from noise. An example of where this approach is effective in avoiding wrong signals is as follows: when an analyst has a 'buy' recommendation on a stock and the share price subsequently falls, the analyst may reduce their target price to be more realistic, but still maintain their buy recommendation because the stock is now even cheaper. The paper also provides a reasonable argument that target price upgrades can provide additional information above a 'strong buy' recommendation because it indicates added conviction when further recommendation upgrades aren't possible (and vice versa for downgrades).

The following chart shows the one-month abnormal return for a stock with large target price upgrades as well as downgrades within different recommendation categories. A target price revision is classified as large when it is within the top or bottom quintile (1/5th) of past revisions in their dataset. Returns are measured over a one month period and numbers are annualised. The authors assume a one day delay before trading on target price revisions, which is quite conservative. We have taken these numbers from Table 4 in the Kanne et al (2012) paper and annualised them. It is clear that target price upgrades perform better within the positive recommendation categories, while target price downgrades underperform the most within the negative recommendation categories. Note that the authors combine the 'sell' and 'strong sell' categories because the data for these is quite sparse.

Figure 7: Annualised abnormal returns for target price revisions in different recommendation categories



Investment portfolios can therefore benefit from tilts on the best and worst performing categories in terms of target price revisions within recommendation categories. A sensible long-short investment strategy is therefore to buy the stocks with large target price upgrades in the buy/strong buy categories and short the stocks with large target price downgrades in the sell/strong sell categories. In their back tests this produces an abnormal return of 21.9% pa.

The authors repeat the back test for target price revisions that coincide with recommendation revisions. A strategy that goes long stocks with target price upgrades and simultaneous recommendation upgrades to buy/strong buy,

while shorting stocks with target price downgrades and simultaneous recommendation downgrades to sell/strong sell, with each trade held for one month, earns an annualised return of 27.4% in their back test. This strategy, however, may not produce a very consistent stream of trading opportunities because the bar is set very high.

As part of their analysis, the authors also uncover interesting facts about typical analyst behaviour. For example, target price revisions usually (85% of the time) occur independently of recommendation revisions. Analysts also tend to revise their target prices down after a drop in the share price, but they usually do not revise their target prices up after a run-up in the share price.

Buy initiations offer incremental value ➤

Initiation of analyst coverage tends to be followed by a permanent increase in liquidity and generally positive abnormal returns


It takes a certain commitment - in terms of time and effort - for sell-side analysts to initiate research coverage on a firm. Analysts should therefore be more inclined to initiate coverage when they believe a share price is under-valued or over-valued and that its purchase or sale would be of significant value to their clients. There are a number of additional reasons why analysts may initiate coverage where the argument for share price support is less clear. But despite these different incentives, evidence suggests that the majority of initiations impact share prices positively through a permanent improvement in liquidity and that the overall initiation effect tends to be positive.

Paul Irvine (2003) investigates the price impact of new buy/hold/sell recommendations for initiations and finds the price impact to be stronger than for analysts with existing coverage (termed as 'continuations'). For example, initiations with a 'strong buy' recommendation beat the market on average by 1.49% while continuations beat the market by a lesser 0.75% (the difference is highly significant with a t-stat of 2.13) in the two days around an initiation.

His data sample consists of 1259 analyst initiations in the US market, during 1995, within the IBES database. For comparative purposes he matches each initiation with a 'continuation' observation for the same stock and calendar quarter.

Initiations of coverage normally happen *after* large share price moves. Positive initiations tend to be followed by additional positive momentum in the share price over the next 12 months, which merits further investigation.

Figure 8: Event study to show the monthly cumulative abnormal returns around initiations of coverage



OUR QUANTITATIVE SCREEN BASED ON THESE IDEAS

We recommend sensible metrics to screen the most attractive stocks according to the ideas set out in this document. The stock screen on the front page (Table 1) takes advantage of the vast CIMB coverage of almost 1000 stocks across Asia.

Our screen makes use of the following findings:

- Initiations with positive recommendations tend to beat the market going forward because of both the analyst signal and a general uplift in liquidity.
- Stocks upgraded to a positive recommendation tend to beat the market going forward.
- Stocks downgraded to a negative recommendation tend to underperform the market going forward.
- Upgrades in target price for stocks with a positive recommendation tend to beat the market going forward.
- Downgrades in target price for stocks with a negative recommendation tend to underperform the market going forward.

The papers we highlight all show relatively fast time decay in the informational value of analyst revisions, and we allow for this in our quant scores. Both the ‘recommendation score’ and ‘target price’ scores apply an exponential time weighting, which assigns higher weight to more recent recommendations or target price revisions.


For the ‘recommendation score’, new positive initiations are assigned a score of +1, upgrades to a positive recommendation are also assigned +1, while downgrades to a negative recommendation are assigned a score of -1. These scores are then deflated by an exponential time decay factor, with a half-life of 30 calendar days. In other words, the time decay factor is 1.0 on the day of an analyst revision, decaying exponentially to exactly 0.5 when reaching 30 calendar days after the revision occurred.

As above, a ‘target price score’ of +1 is assigned to stocks with an upgrade in target price (greater than +10%) and a simultaneous positive analyst recommendation, while a score of -1 is assigned to a stock with a downgrade in target price (greater than -10%) and a simultaneous negative analyst recommendation. The same time decay factor is applied as described above.

$$\text{Score} = +/-1 * \exp(\# \text{ days since revision} * \log(0.5) / 30)$$

The ‘total score’ is simply a sum of the ‘recommendation score’ and the ‘target price score’.

Figure 9: Exponential time decay function with 30-day half-life



SOURCE: CIMB

REFERENCES

- Barber, B, Lehavy, R, McNichols, M and Trueman, B. "Reassessing the returns to analysts' stock recommendations." *Financial Analysts Journal* (2003): 88-96.
- Barber, BM & Lehavy, R. "Ratings changes, ratings levels, and the predictive value of analysts recommendations." *Financial management* 39.2 (2010): 533-553.
- Boni, L, and Womack, KL. "Analysts, industries, and price momentum." *Journal of Financial and Quantitative Analysis* 41.01 (2006): 85-109.
- Irvine, PJ. "The incremental impact of analyst initiation of coverage." *Journal of Corporate Finance* 9.4 (2003): 431-451.
- Jegadeesh, N, and Kim, W. "Value of analyst recommendations: International evidence." *Journal of Financial Markets* 9.3 (2006): 274-309.
- Kanne, S, Klobucnik, J, Kreutzmann, D and Sievers, S. "To buy or not to buy? The value of contradictory analyst signals." *Financial Markets and Portfolio Management* 26.4 (2012): 405-428.

Figure 10: CIMB regional quantitative team details

Quantitative Research

Eben van Wyk	Australia	+61 2 9694 6058	eben.van.wyk@cimb.com
Rohit Sharma	Hong Kong	+852 2539 1313	rohit.sharma@cimb.com
Sushil Kedia	India	+91 22 6602 5209	sushil.kedia@cimb.com
Wei Lu	Australia	+61 2 9694 6069	wei.lu@cimb.com

Quantitative Strategy

Andrew Tang	Australia	+61 2 9694 6076	andrew.tang@cimb.com
-------------	-----------	-----------------	----------------------

Trading Research and Algorithmic Trading

Andrew Freyre-Sanders	Hong Kong	+852 2539 1368	andrew.freyre-sanders@cimb.com
Alex Chen	Hong Kong	+852 2532 1132	alex.chen@cimb.com
Ken Wessen	Australia	+61 2 9694 5068	ken.wessen@cimb.com
Richard Knight	Australia	+61 2 9694 5069	richard.knight@cimb.com

Database & Quant Screening

Thiva Nagaratnam	Australia	+61 2 9694 6056	thiva.nagaratnam@cimb.com
Muditha Weeratunga	Australia	+61 2 9694 6057	muditha.weeratunga@cimb.com
James Barrett	Hong Kong	+852 2539 1318	james.barrett@cimb.com
Piyanchuk Sanongkun	Thailand	+66 2657 9234	piyanchuk.sa@cimb.com

SOURCE: CIMB

DISCLAIMER

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

By accepting this report, the recipient hereof represents and warrants that he is entitled to receive such report in accordance with the restrictions set forth below and agrees to be bound by the limitations contained herein (including the "Restrictions on Distributions" set out below). Any failure to comply with these limitations may constitute a violation of law. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMB.

Unless otherwise specified, this report is based upon sources which CIMB considers to be reasonable. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research.

Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of CIMB or its affiliates to any person to buy or sell any investments.

CIMB, its affiliates and related companies, their directors, associates, connected parties and/or employees may own or have positions in securities of the company(ies) covered in this research report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities. Further, CIMB, its affiliates and its related companies do and seek to do business with the company(ies) covered in this research report and may from time to time act as market maker or have assumed an underwriting commitment in securities of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) as well as solicit such investment, advisory or other services from any entity mentioned in this report.

CIMB or its affiliates may enter into an agreement with the company(ies) covered in this report relating to the production of research reports. CIMB may disclose the contents of this report to the company(ies) covered by it and may have amended the contents of this report following such disclosure.

The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report. CIMB prohibits the analyst(s) who prepared this research report from receiving any compensation, incentive or bonus based on specific investment banking transactions or for providing a specific recommendation for, or view of, a particular company. Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/her coverage of company(ies) in the performance of his/her duties or the performance of his/her recommendations and the research personnel involved in the preparation of this report may also participate in the solicitation of the businesses as described above. In reviewing this research report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request.

Reports relating to a specific geographical area are produced by the corresponding CIMB entity as listed in the table below. The term "CIMB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, CIMB Group Holdings Berhad ("CIMBGH") and its affiliates, subsidiaries and related companies.

Country	CIMB Entity	Regulated by
Australia	CIMB Securities (Australia) Limited	Australian Securities & Investments Commission
Hong Kong	CIMB Securities Limited	Securities and Futures Commission Hong Kong
Indonesia	PT CIMB Securities Indonesia	Financial Services Authority of Indonesia
India	CIMB Securities (India) Private Limited	Securities and Exchange Board of India (SEBI)
Malaysia	CIMB Investment Bank Berhad	Securities Commission Malaysia
Singapore	CIMB Research Pte. Ltd.	Monetary Authority of Singapore
South Korea	CIMB Securities Limited, Korea Branch	Financial Services Commission and Financial Supervisory Service
Taiwan	CIMB Securities Limited, Taiwan Branch	Financial Supervisory Commission
Thailand	CIMB Securities (Thailand) Co. Ltd.	Securities and Exchange Commission Thailand

(i) As of September 24, 2013, CIMB has a proprietary position in the securities (which may include but not limited to shares, warrants, call warrants and/or any other derivatives) in the following company or companies covered or recommended in this report:

(a) Banpu, National Australia Bank, RHB Capital Bhd, SIA Engineering

(ii) As of September 25, 2013, the analyst(s) who prepared this report, has / have an interest in the securities (which may include but not limited to shares, warrants, call warrants and/or any other derivatives) in the following company or companies covered or recommended in this report:

(a) -

The information contained in this research report is prepared from data believed to be correct and reliable at the time of issue of this report. CIMB may or may not issue regular reports on the subject matter of this report at any frequency and may cease to do so or change the periodicity of reports at any time. CIMB is under no obligation to update this report in the event of a material change to the information contained in this report. This report does not purport to contain all the information that a prospective investor may require. CIMB or any of its affiliates does not make any guarantee, representation or warranty, express or implied, as to the adequacy, accuracy, completeness, reliability or fairness of any such information and opinion contained in this report. Neither CIMB nor any of its affiliates nor its related persons shall be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

This report is general in nature and has been prepared for information purposes only. It is intended for circulation amongst CIMB and its affiliates' clients generally and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. The information and opinions in this report are not and should not be construed or considered as an offer, recommendation or solicitation to buy or sell the subject securities, related investments or other financial instruments thereof. Investors are advised to make their own independent evaluation of the information contained in this research report, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as to the legal, business, financial, tax and other aspects before participating in any transaction in respect of the securities of company(ies) covered in this research report. The securities of such company(ies) may not be eligible for sale in all jurisdictions or to all categories of investors.

Australia: Despite anything in this report to the contrary, this research is provided in Australia by CIMB Securities (Australia) Limited ("CSAL") (ABN 84 002 768 701, AFS Licence number 240 530). CSAL is a Market Participant of ASX Ltd, a Clearing Participant of ASX Clear Pty Ltd, a Settlement Participant of ASX Settlement Pty Ltd, and, a participant of Chi X Australia Pty Ltd. This research is only available in Australia to persons who are "wholesale clients" (within the meaning of the Corporations Act 2001 (Cth)) and is supplied solely for the use of such wholesale clients and shall not be distributed or passed on to any other person. This research has been prepared without taking into account the objectives, financial situation or needs of the individual recipient.

France: Only qualified investors within the meaning of French law shall have access to this report. This report shall not be considered as an offer to subscribe to, or used in connection with, any offer for subscription or sale or marketing or direct or indirect distribution of financial instruments and it is not intended as a solicitation for the purchase of any financial instrument.

Hong Kong: This report is issued and distributed in Hong Kong by CIMB Securities Limited ("CHK") which is licensed in Hong Kong by the Securities and Futures Commission for Type

1 (dealing in securities), Type 4 (advising on securities) and Type 6 (advising on corporate finance) activities. Any investors wishing to purchase or otherwise deal in the securities covered in this report should contact the Head of Sales at CIMB Securities Limited. The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Services Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CHK has no obligation to update its opinion or the information in this research report.

This publication is strictly confidential and is for private circulation only to clients of CHK. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CHK. Unless permitted to do so by the securities laws of Hong Kong, no person may issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the securities covered in this report, which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong).

India: This report is issued and distributed in India by CIMB Securities (India) Private Limited ("CIMB India") which is registered with SEBI as a stock-broker under the Securities and Exchange Board of India (Stock Brokers and Sub-Brokers) Regulations, 1992 and in accordance with the provisions of Regulation 4 (g) of the Securities and Exchange Board of India (Investment Advisers) Regulations, 2013, CIMB India is not required to seek registration with SEBI as an Investment Adviser.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of CIMB India and they have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues, client feedback and competitive factors. Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed or proposed to be performed by CIMB India or its affiliates.

Indonesia: This report is issued and distributed by PT CIMB Securities Indonesia ("CIMBI"). The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Services Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CIMBI has no obligation to update its opinion or the information in this research report.

This publication is strictly confidential and is for private circulation only to clients of CIMBI. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMBI. Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesia residents except in compliance with applicable Indonesian capital market laws and regulations.

Malaysia: This report is issued and distributed by CIMB Investment Bank Berhad ("CIMB"). The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Services Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CIMB has no obligation to update its opinion or the information in this research report.

This publication is strictly confidential and is for private circulation only to clients of CIMB. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMB.

New Zealand: In New Zealand, this report is for distribution only to persons whose principal business is the investment of money or who, in the course of, and for the purposes of their business, habitually invest money pursuant to Section 3(2)(a)(ii) of the Securities Act 1978.

Singapore: This report is issued and distributed by CIMB Research Pte Ltd ("CIMBR"). Recipients of this report are to contact CIMBR in Singapore in respect of any matters arising from, or in connection with, this report. The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Services Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CIMBR has no obligation to update its opinion or the information in this research report.

This publication is strictly confidential and is for private circulation only. If the recipient of this research report is not an accredited investor, expert investor or institutional investor, CIMBR accepts legal responsibility for the contents of the report without any disclaimer limiting or otherwise curtailing such legal responsibility. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMBR.

As of September 24, 2013, CIMBR does not have a proprietary position in the recommended securities in this report.

South Korea: This report is issued and distributed in South Korea by CIMB Securities Limited, Korea Branch ("CIMB Korea") which is licensed as a cash equity broker, and regulated by the Financial Services Commission and Financial Supervisory Service of Korea.

The views and opinions in this research report are our own as of the date hereof and are subject to change, and this report shall not be considered as an offer to subscribe to, or used in connection with, any offer for subscription or sale or marketing or direct or indirect distribution of financial investment instruments and it is not intended as a solicitation for the purchase of any financial investment instrument.

This publication is strictly confidential and is for private circulation only, and no part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMB Korea.

Sweden: This report contains only marketing information and has not been approved by the Swedish Financial Supervisory Authority. The distribution of this report is not an offer to sell to any person in Sweden or a solicitation to any person in Sweden to buy any instruments described herein and may not be forwarded to the public in Sweden.

Taiwan: This research report is not an offer or marketing of foreign securities in Taiwan. The securities as referred to in this research report have not been and will not be registered with the Financial Supervisory Commission of the Republic of China pursuant to relevant securities laws and regulations and may not be offered or sold within the Republic of China through a public offering or in circumstances which constitutes an offer or a placement within the meaning of the Securities and Exchange Law of the Republic of China that requires a registration or approval of the Financial Supervisory Commission of the Republic of China.

Thailand: This report is issued and distributed by CIMB Securities (Thailand) Company Limited (CIMBS). The views and opinions in this research report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Services Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CIMBS has no obligation to update its opinion or the information in this research report.

This publication is strictly confidential and is for private circulation only to clients of CIMBS. This publication is being supplied to you strictly on the basis that it will remain confidential. No part of this material may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of CIMBS.

Corporate Governance Report:

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. CIMBS does not confirm nor certify the accuracy of such survey result.

Score Range:	90 – 100	80 – 89	70 – 79	Below 70 or	No Survey Result
Description:	Excellent	Very Good	Good	N/A	

United Arab Emirates: The distributor of this report has not been approved or licensed by the UAE Central Bank or any other relevant licensing authorities or governmental agencies in the United Arab Emirates. This report is strictly private and confidential and has not been reviewed by, deposited or registered with UAE Central Bank or any other licensing authority or governmental agencies in the United Arab Emirates. This report is being issued outside the United Arab Emirates to a limited number of institutional investors and must not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose. Further, the information contained in this report is not intended to lead to the sale of investments under any subscription agreement or the conclusion of any other contract of whatsoever nature within the territory of the United Arab Emirates.

United Kingdom and Europe: In the United Kingdom and European Economic Area, this report is being disseminated by CIMB Securities (UK) Limited ("CIMB UK"). CIMB UK is authorised and regulated by the Financial Services Authority and its registered office is at 27 Knightsbridge, London, SW1X 7YB. This report is for distribution only to, and is solely

directed at, selected persons on the basis that those persons: (a) are persons that are eligible counterparties and professional clients of CIMB UK; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (c) are persons falling within Article 49 (2) (a) to (d) ("high net worth companies, unincorporated associations etc") of the Order; (d) are outside the United Kingdom; or (e) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with any investments to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Only where this report is labelled as non-independent, it does not provide an impartial or objective assessment of the subject matter and does not constitute independent "investment research" under the applicable rules of the Financial Services Authority in the UK. Consequently, any such non-independent report will not have been prepared in accordance with legal requirements designed to promote the independence of investment research and will not subject to any prohibition on dealing ahead of the dissemination of investment research.

United States: This research report is distributed in the United States of America by CIMB Securities (USA) Inc, a U.S.-registered broker-dealer and a related company of CIMB Research Pte Ltd, CIMB Investment Bank Berhad, PT CIMB Securities Indonesia, CIMB Securities (Thailand) Co. Ltd, CIMB Securities Limited, CIMB Securities (Australia) Limited, CIMB Securities (India) Private Limited, and is distributed solely to persons who qualify as "U.S. Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934. This communication is only for Institutional Investors whose ordinary business activities involve investing in shares, bonds and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not a U.S. Institutional Investor or Major Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. CIMB Securities (USA) Inc, is a FINRA/SIPC member and takes responsibility for the content of this report. For further information or to place an order in any of the above-mentioned securities please contact a registered representative of CIMB Securities (USA) Inc.

Other jurisdictions: In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is only for distribution to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Distribution of stock ratings and investment banking clients for quarter ended on 31 August 2013		
1211 companies under coverage		
	Rating Distribution (%)	Investment Banking clients (%)
Outperform/Buy/Trading Buy	50.5%	7.2%
Neutral	34.1%	4.8%
Underperform/Sell/Trading Sell	15.4%	4.9%

Recommendation Framework #1 *

Stock

OUTPERFORM: The stock's total return is expected to exceed a relevant benchmark's total return by 5% or more over the next 12 months.

NEUTRAL: The stock's total return is expected to be within +/-5% of a relevant benchmark's total return.

UNDERPERFORM: The stock's total return is expected to be below a relevant benchmark's total return by 5% or more over the next 12 months.

TRADING BUY: The stock's total return is expected to exceed a relevant benchmark's total return by 5% or more over the next 3 months.

TRADING SELL: The stock's total return is expected to be below a relevant benchmark's total return by 5% or more over the next 3 months.

Sector

OVERWEIGHT: The industry, as defined by the analyst's coverage universe, is expected to outperform the relevant primary market index over the next 12 months.

NEUTRAL: The industry, as defined by the analyst's coverage universe, is expected to perform in line with the relevant primary market index over the next 12 months.

UNDERWEIGHT: The industry, as defined by the analyst's coverage universe, is expected to underperform the relevant primary market index over the next 12 months.

TRADING BUY: The industry, as defined by the analyst's coverage universe, is expected to outperform the relevant primary market index over the next 3 months.

TRADING SELL: The industry, as defined by the analyst's coverage universe, is expected to underperform the relevant primary market index over the next 3 months.

* This framework only applies to stocks listed on the Singapore Stock Exchange, Bursa Malaysia, Stock Exchange of Thailand, Jakarta Stock Exchange, Australian Securities Exchange, Taiwan Stock Exchange and National Stock Exchange of India/Bombay Stock Exchange. Occasionally, it is permitted for the total expected returns to be temporarily outside the prescribed ranges due to extreme market volatility or other justifiable company or industry-specific reasons.

CIMB Research Pte Ltd (Co. Reg. No. 198701620M)

Recommendation Framework #2 **

Stock

OUTPERFORM: Expected positive total returns of 10% or more over the next 12 months.

NEUTRAL: Expected total returns of between -10% and +10% over the next 12 months.

UNDERPERFORM: Expected negative total returns of 10% or more over the next 12 months.

TRADING BUY: Expected positive total returns of 10% or more over the next 3 months.

TRADING SELL: Expected negative total returns of 10% or more over the next 3 months.

Sector

OVERWEIGHT: The industry, as defined by the analyst's coverage universe, has a high number of stocks that are expected to have total returns of +10% or better over the next 12 months.

NEUTRAL: The industry, as defined by the analyst's coverage universe, has either (i) an equal number of stocks that are expected to have total returns of +10% (or better) or -10% (or worse), or (ii) stocks that are predominantly expected to have total returns that will range from +10% to -10%; both over the next 12 months.

UNDERWEIGHT: The industry, as defined by the analyst's coverage universe, has a high number of stocks that are expected to have total returns of -10% or worse over the next 12 months.

TRADING BUY: The industry, as defined by the analyst's coverage universe, has a high number of stocks that are expected to have total returns of +10% or better over the next 3 months.

TRADING SELL: The industry, as defined by the analyst's coverage universe, has a high number of stocks that are expected to have total returns of -10% or worse over the next 3 months.

** This framework only applies to stocks listed on the Korea Exchange, Hong Kong Stock Exchange and China listings on the Singapore Stock Exchange. Occasionally, it is permitted for the total expected returns to be temporarily outside the prescribed ranges due to extreme market volatility or other justifiable company or industry-specific reasons.

Corporate Governance Report of Thai Listed Companies (CGR). CG Rating by the Thai Institute of Directors Association (IOD) in 2012.

AAV – not available, ADVANC - Excellent, AEONTS - Good, AMATA - Very Good, ANAN – not available, AOT - Excellent, AP - Very Good, BANPU - Excellent , BAY - Excellent , BBL - Excellent, BCH – not available, BCP - Excellent, BEC - Very Good, BGH - not available, BJC – Very Good, BH - Very Good, BIGC - Very Good, BTS - Excellent, CCET - Good, CENTEL – Very Good, CK - Very Good, CPALL - Very Good, CPF - Very Good, CPN - Excellent, DELTA - Very Good, DTAC - Very Good, EGCO - Excellent, ERW – Excellent, GLOBAL - Good, GLOW - Very Good, GRAMMY – Excellent, HANA - Very Good, HEMRAJ - Excellent, HMPRO - Very Good, INTUCH – Very Good, ITD – Very Good, IVL - Very Good, JAS – Very Good, KAMART – not available, KBANK - Excellent, KK – Excellent, KTB - Excellent, LH - Very Good, LPN - Excellent, MAJOR - Good, MAKRO – Very Good, MCOT - Excellent, MINT - Very Good, PS - Excellent, PSL - Excellent, PTT - Excellent, PTTGC - Excellent, PTTEP - Excellent, QH - Excellent, RATCH - Excellent, ROBINS - Excellent, RS – Excellent, SAMART – Excellent, SC – Excellent, SCB - Excellent, SCC - Excellent, SCCC - Very Good, SIRI - Good, SPALI - Very Good, SRICHA – not available, SSI – not available, STA - Good, STEC - Very Good, TCAP - Very Good, THAI - Excellent, THCOM – Very Good, TICON – Very Good, TISCO - Excellent, TMB - Excellent, TOP - Excellent, TRUE - Very Good, TTW – Very Good, TUF - Very Good, VGI – not available, WORK – Good.